Similarly, when an MDA-MB-453 xenograft study was performed with low-dose and high-dose enzalutamide treatments initiated when the tumors reached 100 mm3 (Figure S4A in Additional file4), tumor growth was decreased in a dose-dependent manner (Figure S4B in Additional file4) and was associated with significantly reduced nuclear AR staining in enzalutamide-treated tumors (Figure S4C in Additional file4). The gene discussed is AR; the disease is neoplasm.